I-Mab (IMAB) News Mentions Statistics 2024

0 100%

1W 0% 1M 100% 3M 100%

Est. daily news mentions.

Similar companies

Company		News Mentions
	Amgen AMGN	0 100%
	Gilead Sciences GILD	0 0%
	Catalyst Pharmaceuticals CPRX	0 0%
	Inovio Pharmaceuticals INO	0 100%
	Anavex Life Sciences AVXL	0 0%

I-Mab to Participate at the Piper Sandler Healthcare Conference

November 20

I-Mab’s (IMAB) Buy Rating Reaffirmed at HC Wainwright

November 19

I-Mab Third Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023)

November 16

Month over Month

Est. daily news mentions.

Oct 2024	0	3.2%
Sep 2024	0	24.2%
Aug 2024	0	66.7%
Jul 2024	0	16.1%
Jun 2024	0

How often is I-Mab mentioned in the news?

I-Mab was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is I-Mab performing compared to its industry peers?

I-Mab underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of I-Mab in the last month?

I-Mab's was mentioned in fewer articles yesterday, compared to the same day last month.

Why is it important to track news mentions for I-Mab?

By monitoring mentions in the news for I-Mab, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of I-Mab, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

Top Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact

I-Mab (IMAB) - News Mentions

Similar companies

Amgen

Gilead Sciences

Catalyst Pharmaceuticals

Inovio Pharmaceuticals

Anavex Life Sciences

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab’s (IMAB) Buy Rating Reaffirmed at HC Wainwright

I-Mab Third Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023)

I-Mab Reports Third Quarter 2024 Results

I-Mab (IMAB) to Release Earnings on Thursday

I-Mab (IMAB) Scheduled to Post Quarterly Earnings on Thursday

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

IMAB Stock Plummets Amidst Broader Biotech Industry Decline

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

I-Mab to Participate at the Truist Securities BioPharma Symposium

I-Mab Biopharma’s Strategic US Transition and Pipeline Focus

IMAB Stock Dips Over 5% Amidst Mixed Financial Performance

I-Mab (NASDAQ:IMAB) Sees Significant Drop in Short Interest

I-Mab (NASDAQ:IMAB) Sees Significant Decrease in Short Interest

IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade

Month over Month

How often is I-Mab mentioned in the news?

Analyzing News Mentions, how is I-Mab performing compared to its industry peers?

Has there been an increase or decrease in news mentions of I-Mab in the last month?

Why is it important to track news mentions for I-Mab?